ArticleCNS neuroscience & therapeutics2020
B3GNT5 is a novel marker correlated with stem-like phenotype and poor clinical outcome in human gliomas.
Article in CNS neuroscience & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Genome-wide DNA methylation profiling during metabolic dysfunction-associated steatohepatitis-related hepatocarcinogenesis in patients in Japan and the United States.Scientific reports · 2026Article
- Ensemble Machine Learning Approaches Predict Survival in Lower-Grade Glioma Based on Glycosphingolipid Gene Expression and Metabolic Modeling.Computational and structural biotechnology journal · 2026Article
- Article
- Building simplified cancer subtyping and prediction models with glycan gene signatures.Cell reports methods · 2025Article
- B3GNT5 is a novel marker correlated with malignant phenotype and poor outcome in pancreatic cancer.iScience · 2024Article
- Pan-cancer analysis of B3GNT5 with potential implications for cancer immunotherapy and cancer stem cell stemness.PloS one · 2024Article
- Article
- Downregulation of ADAMTS3 Suppresses Stemness and Tumorigenicity in Glioma Stem Cell.CNS neuroscience & therapeutics · 2023Article
- β3GNT9 as a prognostic biomarker in glioblastoma and its association with glioblastoma immune infiltration, migration and invasion.Frontiers in oncology · 2023Article
- The role of B3GNT3 as an oncogene in the growth, invasion and migration of esophageal cancer cells.Acta cirurgica brasileira · 2023Article
- Sprouty 1 is associated with stemness and cancer progression in glioblastoma.IBRO neuroscience reports · 2022Article
- Elevated transcription and glycosylation of B3GNT5 promotes breast cancer aggressiveness.Journal of experimental & clinical cancer research : CR · 2022Article
- Review
- Potential biomarkers of acute myocardial infarction based on co-expression network analysis.Experimental and therapeutic medicine · 2022Article
- Genome-Wide Analysis for the Regulation of Gene Alternative Splicing by DNA Methylation Level in Glioma and its Prognostic Implications.Frontiers in genetics · 2022Article
- lncRNA MIR4435‑2HG promotes the progression of liver cancer by upregulating B3GNT5 expression.Molecular medicine reports · 2022Article
- O-Glycosylating Enzyme GALNT2 Predicts Worse Prognosis in Cervical Cancer.Pathology oncology research : POR · 2022Article
- Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study.CNS neuroscience & therapeutics · 2021Article
- Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma.CNS neuroscience & therapeutics · 2021Review
- B3GNT5 is a novel marker correlated with stem-like phenotype and poor clinical outcome in human gliomas.CNS neuroscience & therapeutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsGlioblastoma multiforme (GBM) is the most lethal tumor with a median patient survival of 14 to 15 months. Glioma stem cells (GSCs) play a critical role in tumor initiation and therapeutic resistance in GBM. B3GNT5 has been suggested as the key glycosyltransferase in the biosynthesis of the (neo-) lacto series of glycosphingolipid. In this study, we evaluated the B3GNT5 expression in GSCs as well as the correlation with clinical data in GBM.
methodsThe mRNA levels of B3GNT5 in normal astrocytes, four glioma cell lines, and four GSCs were evaluated using real-time PCR. Small interference RNAs (siRNAs) were used to inhibit B3GNT5 expression and analyze its ability to form neurospheres. Statistical analyses were conducted to determine the association with B3GNT5 expression and tumor grade and GBM subtypes as well as patient survival using public datasets.
resultsB3GNT5 expression was significantly elevated in GSCs compared with normal astrocytes, glioma cell lines, and their matched differentiated tumor cells. Knockdown of B3GNT5 in GSCs decreased the neurosphere formation. Patients with high B3GNT5 expression had a short overall survival. B3GNT5 is correlated with classical and mesenchymal GBM subtypes.
conclusionThe findings suggest the central role of B3GNT5 in regulating malignancy of GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.